Maitland J A, Millar B C, Bell J B, Montes A, Treleaven J, Gore M E, McElwain T J
Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
Br J Cancer. 1990 Mar;61(3):429-33. doi: 10.1038/bjc.1990.94.
Myeloma colonies (MY-CFUc) could be grown in vitro for 6 months (median time) after a group of 12 myeloma patients had reached complete remission (CR). In a second group of 25 patients MY-CFUc increased in 17/25 and GM-CFUc in 20/25 patients after cyclophosphamide even though 24/25 patients had a partial response to VAMP and one was in CR. These data suggest that cell killing by cyclophosphamide stimulates residual tumour cells into proliferation and adds further support to the idea that myeloma is under some degree of homeostatic control which may be analogous to that in normal bone marrow. Although lymphoplasmacytoid myeloma cells may be more drug resistant than plasmacytoid myeloma cells in vitro, it was not possible to conclude that the emergence of lymphoplasmacytoid cells at relapse was indicative of resistance to further treatment.
在一组12例骨髓瘤患者达到完全缓解（CR）后，骨髓瘤集落（MY-CFUc）能够在体外培养6个月（中位时间）。在第二组25例患者中，尽管24/25例患者对VAMP有部分反应且1例处于CR，但环磷酰胺治疗后17/25例患者的MY-CFUc增加，20/25例患者的GM-CFUc增加。这些数据表明，环磷酰胺导致的细胞杀伤刺激残留肿瘤细胞增殖，并进一步支持了骨髓瘤处于某种程度的稳态控制之下这一观点，这种稳态控制可能类似于正常骨髓中的情况。虽然在体外淋巴浆细胞样骨髓瘤细胞可能比浆细胞样骨髓瘤细胞更具耐药性，但无法得出复发时淋巴浆细胞样细胞的出现表明对进一步治疗耐药的结论。
